Vai ai contenuti. | Spostati sulla navigazione | Spostati sulla ricerca | Vai al menu | Contatti | Accessibilità

| Crea un account

Silvia, Ferrazzoni (2008) Risposta delle vie aeree indotta da inquinanti ambientali valutata con metodiche prevalentemente non invasive. [Tesi di dottorato]

Full text disponibile come:

Documento PDF
Documento PDF
Documento PDF

Abstract (inglese)

Inflammation is the main responsible for bronchial hyperresponsiveness, airflow limitation and mucus hypersecretion in chronic obstructive pulmonary diseases as for example in asthma. This has brought us to extensively investigate into the cells types and mediators responsible for the cascade of events which lead from the initial stimulus to an altered airway function.
In the past the main function of the respiratory epithelium was thought to be an inert barrier. It is, in fact, the interface between the internal milieu and the external environment. The bronchial epithelium actually answers external environment changes by freeing a large number of molecules and mediators which modify the lining fluid pH, transmit signals to the immunitary system cells and draws inflammatory cells into the airway lumen.
The expression of inducible form of nitric oxide synthase (iNOS) in the airway epithelium, responsible for the concentration of nitric oxide exhaled (eNO) detectable in the exhaled air, is greatly upregulated after exposure to pro-inflammatory cytokines and oxidants agents. For this reason iNOS has been implicated in the pathogenesis of airway inflammatory response. Patients with asthma have a marked increase in NO in exhaled air.
The loss of integrity of the bronchial epithelium can be associated with alterations of the secretory properties and of an increase of permeability. The Clara cell protein (CC16) is a small anti-inflammatory and immunosuppressive protein which can take part in the protection of the airway and has been measured out in the liquid for the bronchoalveolar lavage (BAL). Increased levels of CC16 in the serum or in the urine may indicate altered permeability of the epithelium barrier due to lung damage.
Occupational asthma is one of the most common respiratory diseases linked to work, in industrialized countries. Isocyanates are important aetiological agents of occupational asthma: because of their chemical and physical characteristics they have an irritating and sensitizing power. Polymeric resins, which are widely used as paints, foams and elastomers derive from isocyanates polymerization .
The present research has hypothesised that the acute response of the respiratory tract induced by isocyanates in sensitised patients, is characterised by the attraction of inflammatory cells into the airway which can be measured by induced sputum, by a particular profile of mediators freed by the epithelium in the exhaled breath, by lining fluid alterations quantifiable in the exhaled breath condensate (pH) and by a bronchiolar damage on measuring mediators peculiar of the airway, in plasma and urine.
In the first phase of the study the measuring methods for exhaled nitric oxide, exhaled breath pH condensate and CC16 in serum and urine were standardized. Then we selected 15 patients with occupational asthma caused by isocyanates, 24 non sensitised control patients and 3 with occupational rhinitis from isocyanates.
Monitoring of the airway acute response was carried out by comparing patients with occupational asthma with the control ones.
Each patient was experimentally exposed to isocyanates concentrations (TDI,MDI or HDI) below TLV Stel (20ppb) and to placebo on different days, in single blind.
The Respiratory function and exhaled NO concentrations were monitored for seven hours after placebo and isocyanates exposure. In order to determine the pH, the exhaled breath condensate was collected seven hours before and after placebo and isocyanates exposure. Later on, subsequent measurements and collections were carried out at the 24th, 48th hours, 7th and 30th days after exposure to ysocianates.
Sputum was induced by hipertonic salty solution aerosol (3-4%) before and 24 hours after exposure. At the same times and 48 hours after exposure venous blood samples and urine were taken in order to determine the clara cell protein (CC16).
The patients with positive specific challenge test (SIC+), in basic situation, presented an eNO concentration of 67.12 ppb[16](geometric mean [SE]). 30 minutes after the specific challenge test, this figure underwent a significant reduction (45 ppb[13.7]) which kept the same values until the second hour after exposure 53.7ppb [14].
Then the eNo concentration increased and reached the highest figure at the 48th hour (118ppb[25]) after exposure. ON the 7th day after exposure eNo had gone back to the basic value. In the control patients, with a negative specific challenge test (SIC-) no variation in the eNO concentration before and after exposure to isocyanates. As for subjects with rhinitis deriving from isocyanates the eNo concentration had a similar course as the control patients'one.
The SIC+ ones showed a meaningful increase in the eosinophils in the induced sputum 24 hours from exposure to ysocianates compared to the basic values (p=0.01). In control patients instead, a meaningful diminution of the percentage of the eosinophils in the sputum 24 hours after exposure to isocyanates (p=0.041) was observed. Moreover a meaningful difference was also observed between the percentage of eosinphilis in the sputum of 24 hours after exposure to isocyanates in test positive patients compared to the control ones (p= 0.0002). No meaningful difference was observed in the neutrophils percentage after exposure to isocyanates in both groups. Grouping all the patients, the variation in the eNo concentration at the 48th hour compared to the basic value (expressed in logarithm) positively correlated with the eosinophils variation (expressed in logarithm) at the 24th hour compared to the basis (p<0.05, rho=0.496).
The pH measurement in the EBC have highlighted a significant increase of the pH at the 7th hour after exposure to placebo (in the afternoon) compared to the basic figures pre-exposure (in the morning) both in the SIC+ and in the SIC- patients, respectively with a significance of p=0.005 and p=0.0013. The same pattern was observed, in both groups of patients, on the exposure to isocyanates day, although the differences did not statistical significant.
The basal figures of CC16 in the serum and urine in SIC+ patients were considerably higher than in the SIC- ones: p=0.0282 and p=0.0169 respectively.
After 7 and 24 hours from exposure to isocyanates no significant variation was observed both in the SIC+ and SIC- patients.
In this research it has been demonstrated that the asthmatic reaction induced by isocyanates is linked to a significant increase in the eNo concentration which reaches the highest figure at the 48th hour after exposure. This increase is belated as it reveals when the bronchoconstriction has been resolved; it is also 24 hours post poned with respect to the increase of the eosinophils in the sputum, which in previous studies showed increase between the 8th and the 24th hours shifted and a return to basal values after 48 hours. Moreover,the eosinophils increase seems to prevent the increase of Nitric oxide thus confirming that in bronchial asthma eNo is a sign of airway eosiniphilia. The increase in eosinophils in sputum and the belated one in exhaled eNo are typical of patients developing an asthmatic reaction as these changes have not been osbserved either in control patients or in those with rhinitis from ysocianates. The pH of the condensate in the exhaled breath does not associate with variations linked to the asthmatic reaction induced by isocyanates.
Consequently isocyanates somehow seem to alter the ph circadian rhythm.
To conclude, patients with bronchial asthma from isocyanates showed a CC16 basic value higher both in the serum and urine pre-exposure with respect to control subjects, which suggests that in asthma there is an alteration of the bronchiolar epithelium in basic situations. A severe exposition to ysocianates does not imply meaningful variations of CC16 in serum and urine.

Statistiche Download - Aggiungi a RefWorks
Tipo di EPrint:Tesi di dottorato
Relatore:Maestrelli, Piero
Dottorato (corsi e scuole):Ciclo 20 > Scuole per il 20simo ciclo > TERRITORIO, AMBIENTE, RISORSE E SALUTE > MEDICINA AMBIENTALE: NUTRIZIONE E INQUINAMENTO
Data di deposito della tesi:2008
Anno di Pubblicazione:2008
Parole chiave (italiano / inglese):asma occupazionale, espettorato indotto, ossido nitrico esalato, pH condensato, CC16 sierica ed urinaria
Settori scientifico-disciplinari MIUR:Area 06 - Scienze mediche > MED/44 Medicina del lavoro
Struttura di riferimento:Dipartimenti > pre 2012 Dipartimento di Medicina Ambientale e Sanità pubblica
Codice ID:566
Depositato il:24 Nov 2008
Simple Metadata
Full Metadata
EndNote Format


I riferimenti della bibliografia possono essere cercati con Cerca la citazione di AIRE, copiando il titolo dell'articolo (o del libro) e la rivista (se presente) nei campi appositi di "Cerca la Citazione di AIRE".
Le url contenute in alcuni riferimenti sono raggiungibili cliccando sul link alla fine della citazione (Vai!) e tramite Google (Ricerca con Google). Il risultato dipende dalla formattazione della citazione.

1. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxon HO, Pare PD. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:2645-53. Cerca con Google

2. Holtzman MJ, Agapov E, Kim J, Morton JD. Developing the epithelial, viral, and allergic paradigm for asthma. Chest 2003; 123:377s-384s. Cerca con Google

3. Knight DA, Volgate ST. The airway epithelium: structural and functional properties in health and disease. Respirology, 2003; 8: 432-446. Cerca con Google

4. Jorens PG, Sibille Y, Goulding NJ, Van Overveld FJ, Herman AG, Bossaert L, Backer WA, Lauwerys R, Flower RJ, Bernard A. Potential role of Clara cell protein, an endogenus phospholipase A2 inhibitor, in acute lung injury. Eur Respir J, 1995; 8: 1647-1653. Cerca con Google

5. Kharitonov S, Alving K, Barnes PJ. Exhaled and nasal nitric oxide measurements: recommendations. Eur Respir J 1997; 10: 1683-93. Cerca con Google

6. Hunt J. Exhaled breath condensate: an evolving tool for non invasive evaluation of lung disease. J Allergy Clin Immunol 2002; 110: 28-34. Cerca con Google

7. Horvath I, Hunt J, Barnes PJ. Exhaled breath condensate: methodological raccomandations and unresolved questions. ATS/ERS task force on exhaled breath condensate. Eur Respir J 2005; 26:523-548. Cerca con Google

8. Accordino R, Visentin A, Bordin A, Ferrazzoni S, Marian E, Rizzato F, Canova C, Venturini R, Maestrelli P. Long-term repeatability of exhaled breath condensate pH in asthma. Respir Med 2007 Nov 29 (Epub ahead of print). Cerca con Google

9. Hunt J, Fang K, Malik R, Snyder A, Malhotra N, Platts-Mills TA et al. Endogenous airway acidification. Implication for asthma pathophisiology. Am J Respir Crit Care Med 2000; 161:694-699. Cerca con Google

10. Kostikas K, Papatheodorou G, Ganas K, Psathakis K, Panagou P, Loukides S. pH in expired breath condensate of patients with inflammatory airway diseases. Am J Respir Crit 2002; 165:1364-1370. Cerca con Google

11. Janssen LJ. Isoprostanes: an overview and putative roles in pulmonary pathophysiology. Am J Physiol Lung Cell Mol Physiol 2001; 280: L1067-L1082. Cerca con Google

12. Hunt JF, Erwin E, Palmer L, Vaughan J, Malhotra N, Platts-Mills et al. Expression and activity of pH-regulatory glutaminase in the human airway. Am J Respir Crit Care Med 2000; 161:685-687. Cerca con Google

13. Vignola AM, Kips J, Bousquet J. Tissue remodelling as a feature of persistent asthma. J Allergy Clin Immunol 2000; 105: 1041-1053. Cerca con Google

14. Carraro S, Folesani G, Corradi M, Zanconato S, Gaston B, Baraldi E. Acid-base equilibrium in exhaled breath condensate of allergic asthmatic children. Allergy 2005; 60:476-481. Cerca con Google

15. Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE. Standardised methodology of sputum induction and processing. Eur Respir J, September 2002, Volume 20, Spplement 37 Cerca con Google

16. Lemière C. The use of sputum eosinophils in the evaluation of occupational asthma. Curr Opin Allergy Clin Immunol 2004; 4:81-85. Cerca con Google

17. Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ. Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999; 353:2213-2214. Cerca con Google

18. Jatakanon A, Lim S, Barnes PJ. Changes in Sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000; 161:64-72. Cerca con Google

19. Leuppi JD, Salome CM, Jenkins CR, Anderson SD, Xuan W, Marks GB et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001; 163:406-412. Cerca con Google

20. Romagnoli M, Vachier I, Tarodo DIF, et al. Eosinophilic inflammation in sputum of poorly controlled asthmatics. Eur Respir J 2002;20:1370-1377. Cerca con Google

21. Lemière C, Chaboillez S, M alo JL, Cartier A. Changes in sputum cell counts after exposure to occupational agents: what do they mean? J Allergy Clin Immunol 2001¸107:1063-1068. Cerca con Google

22. Alvarez MJ, Estrada JL, Gozalo F, et al. Oilseed rape flow: another allergen causing occupational sthma in farmers. Allergy 2001; 56:185-188. Cerca con Google

23. Maestrelli P, Calcagni P, Saetta M, Di Stefano A, Hosselet JJ, Santonastaso A, Fabbri LM and Mapp CE. Sputum eosinophilia after asthmatic responses induced by isocianates in sensitized subjects. Clin Exp Allergy 1994; 24:29-34. Cerca con Google

24. Obata H, Dittrick M, Chan H, Chan-Yeung. Sputum eosinophils and exhaled nitric oxide during late asthmatic reaction in patients with western red cedar asthma. Eur Respir J 1999; 13: 489-495. Cerca con Google

25. Quirce S, Baeza ML, Tornero P, et al. Occupational asthma caused by exposure to cyanoacrilate. Allergy 2001; 56:446-449. Cerca con Google

26. Lemière C. The use of sputum eosinophils in the evaluation of occupational asthma. Curr Opin Allergy Clin Immunol 2004; 4:81-85. Cerca con Google

27. Park H, Jung K, Kim H et al. Neutrophil activation following TDI bronchial challenger to the airway secretion from subjects with TFI.induced asthma. Clin ExpAllergy 1999; 29:1395-1401. Cerca con Google

28. Lemière C, Romeo P, Chaboillez S, et al. Airway inflammation and functional changes after exposure to different concentrations of isocyanates. J Allery CliN Immunol 2002; 110:641-646. Cerca con Google

29. Douwes J, Gibson P, Pekkanen J, Pearce N. Non-eosinophilic asthma: importance and possible mechanisms. Thorax 2002; 57:643-648. Cerca con Google

30. Liu J, S. Thomas P. Exhaled breath condensate as a method of sampling airway nitric oxide and other markers of inflammation. Med Sci Monit 2005; 11(8): MT53-62. Cerca con Google

31. Silkoff PE, Lent AM, Busacker AA, Katial RK, Balzar S, Strand M, Wenzel SE. Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma. J Allergy Clin Immunol 2005; 116:1249-55. Cerca con Google

32. Taylor DR, Pijnenburg MW, Smith AD, De Jongste JC. Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 2006; 61:817-827. Cerca con Google

33. Kharitonov SA, O’Connor BJ, Ewans DJ, Barnes PJ. Allergen-induced late asthmatic reactions are associated with elevation of exhaled nitric oxide. Am J Respir Crit Care Med 1995; 151 (6):1894-9. Cerca con Google

34. Allmers H, Chen Z, Barbinova L, Marczynski B, Kirschmann V, Baur X. Challenge from methacoline, natural rubber latex, or 4,4-diphenylmethane diisocyanate in workers with suspected sensitization affects exaled nitric oxide (change in exhaled NO levels after allergen challenges). Int Arch Occup Environ health 2000; 73(3):181-6. Cerca con Google

35. Barbinova L, Baur X. Increae in exhaled nitric oxide (eNO) after Work-related isocyanate exposure. Int Arch Occup Environ health 2006; 79:387-395. Cerca con Google

36. Piipari R, Piirila P, Keskinen H, Tuppurainen M, Sovijarvi A, Nordman H. Exhaled nitric oxide in specific challenge test to assess occupational asthma. Eur Respir J 2002; 20:1532-1537. Cerca con Google

37. Van Miert E, Dumont X, Bernard A. CC16 as a marker of lung epithelial hyperpermeability in a acute model of rats exposed to mainstream cigarette smoke. Toxicology letters 2005; 159:115-123. Cerca con Google

38. Hermans C, Petrek M, Kolek V, Weynand B, Pieters T, Lambert M, Bernard A. Serum Clara cell protein (CC16), a marker of the integrity of the air-blood barrier in sarcoidosis. Eur Respir J 2001; 18:507-514. Cerca con Google

39. Shjiubo N, Itoh Y, Yamaguchi T, Sugaya F, Hiarasawa M, Yamada T, Kawai T, Abe S. Serum levels of Clara cell 10-kDa protein are decreased in patients with asthma. Lung 1999; 177:45-52. Cerca con Google

40. Hermans C, Bernard A. Lung epithelium-specific proteins. Am J Crit Care Med 1999; 159:646-678. Cerca con Google

41. Broeckaert F, Bernard A. Clara cell secretory protein (CC16): characteristics and perspectives as lung peripheral biomarker. Clinical and Experimental Allergy 2000; 30:469-475. Cerca con Google

42. Mansur AH, Fryer AA, Hepple M, Strange RC, Spiteri MA. An association study between the Clara cell secretory protein CC16A38G polymorohism and asthma phenotypes. Clin Exp Allergy 2002; 32:994-999. Cerca con Google

43. Robin M, Dong P, Hermans C, Bernard A, Bersten AD, Doyle IR. Serum levels of CC16, SP-A and SP-B reflect tobacco-smoke exposure in asymptomatic subjects. Eur Respir J, 2002; 20:1152-1161. Cerca con Google

44. Timonen KL, Hoek G, Heinrich J, Bernard A, Brunekreef B, Hartog J, Hameri K, Ibald-Mulli A, Mirme A, Peters A, Tittanen P, Kreyling WG, Pekkanen J. Daily variation in fine and ultrafine particulate air pollution and urinary concentractions of lung Clara cell protein CC16. Occup Environ Med 2004; 61:908-914. Cerca con Google

45. Helleday R, Segerstedt B, Forsberg B, Mudway I, Nordberg G, Bernard A, Blomberg A. Exploring the time dependence of serum Clara cell protein as a biomarker of pulmonary injury in humans. Chest 2006 130 (3):672-675. Cerca con Google

46. Arsalane K, Broeckaert F, Knoops B, Clippe A, Buchet JP, Bernard A. Increased serum and urinary concentractions of lung Clara cell protein in rats acutely exposed to ozone. Toxicology and Applied Pharmacology, 1999; 159:169-174. Cerca con Google

47. Michel O, Murdoch R, Bernard A. Inhaled LPS induces blood release of Clara cell specific protein (CC16) in human beings. J Allergy Clin Immunol, 2005; 115:1143-7. Cerca con Google

48. Lagerkvist BJ, Bernard A, Blomberg A, Bergstrom E, Forsberg B, Holmstrom K, Karp K, Lundstrom NG, Segerstedt B, Svensson M, Nordberg G. Pulmonary epithelial integrity in children: relationship to ambient ozone exposure and swimming pool attendance. Environmental Health perspectives 2004; 112 (17):1768-1771. Cerca con Google

49. Mapp CE, Boschetto P, Maestrelli P, Fabbri LM. Occupational asthma. Am J Respir Crit Care Med 2005; 172:280-305. Cerca con Google

50. Bernstein L, Bernstein DI, Chan-Yeung M, Mal JL. Definition an Classification of Asthma in the workplace. In Asthma in the Workplace. New York Taylor & Francis, 2006; p.4. Cerca con Google

51. Mapp CE. Agents, old and new, causing occupational asthma. Occup Environ Med 2001 May;58(5):354-60, 290 Cerca con Google

52. Musk AW, Peters JM, Wegman DH. Isocyanates and respiratory disease: current status. Am J Ind Med 1988; 13: 331-349. Cerca con Google

53. Vainio H, Rosenberg C, Hirvonen A, Norppa H. International Workshop on Biomarkers for isocyanates. Scan J Work Environ Health 1999; 25 (2): 157-159. Cerca con Google

54. Levine SP, Hillig KJD, Dharmarajan V, Spence MW, Baker MD. Critical review of methods of sampling, analys, an monitoring for TDI and MDI. Am Ind Hyg Assoc J 1995; 56: 581-589. Cerca con Google

55. Sari-Minodier I, Charpin D, Signouret M, Poyen D, Vervloet D. Prevalence of self-reported respiratory symptoms in workers exposed to isocyanates. J Occup Environ Med 1999; 41 (7): 582-588. Cerca con Google

56. Lombardo LJ, Balmes JR. Occupational asthma: a review. Environmental Health Perspectives Supplements, August 2000; 108 (suppl 4):697-704. Cerca con Google

57. Malo JL, Chan-Yeung M. Occupational asthma. J Allergy Clin Immunol 2001; 108 (3):317-327. Cerca con Google

58. ATS/ERS Reccommendations for standardized procedures for the online an offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005; 171:912-930. Cerca con Google

59. Miller MR, HanKinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, Van Der Grinten CPM, Gustfsson P, Jensen R, Johnson DC, Macintyre, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338 Cerca con Google

60. Communauté Européenne du Charbon e de l'Acier. Aide-memoir of Spirographic practice for examining ventilatory function.. Industrial Health and Medicine. 2 nd ed. Luxemburg, 1971. Cerca con Google

61. Macintyre N, Crapo RO, Viegi G, Johnson DC, Van Der Grinten CPM, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustfsson P, HanKinson J, Jensen R, McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger J. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26: 720-735. Cerca con Google

62. Cartier A. Definition and diagnosis of occupational asthma. Eur Respir J 1994;7:153-160. Cerca con Google

63. Sheffer AL. International consensus report on diagnosis and treatment of asthma. Eur Respir J 1992;5:601-641. Cerca con Google

64. Meyer JD, Holt DL, Chen Y, Cherry NM, Mc Donald JC. SWORD '99: surveillance work-related and occupational respiratory disease in the UK. Occup Med (London) 2001;51:204-208. Cerca con Google

65. Maestrelli P, Ferrazzoni S, Visentin A, Marian E, Dal Borgo D, Accordino R, Fabbri LM. Measurement of exhaled nitric oxide in healthy adults. Sarcoidosis Vasc Diffuse Lung Dis 2007; 24:65-69. Cerca con Google

66. Piacentini GL, Bodini A, Costella S, Vicentini L, Mazzi P, Sperandio S, Boner AL. Exhaled nitric oxide and sputum eosinophil markers of inflammation in asthmatic children. Eur Respir J. 1999 Jun;13(6):1386-90. Cerca con Google

67. Park H, Jung K, Kim H et al. Neutrophil activation following TDI bronchial challenger to the airway secretion from subjects with TFI induced asthma. Clin ExpAllergy 1999; 29:1395-1401. Cerca con Google

68. Andersson L, Lundberg P-A, Barregard L. Methodological aspects on measurement of Clara cell protein in urine as a biomarker for airway toxicity, compared with serum levels. J Appl. Toxicol. 2007; 27: 60-66. Cerca con Google

69. Baur X, Marek W, Ammon J, et al. Respiratory and other hazards of isocyanates. In Arch Occup Environ Health 1994; 66:141-152. Cerca con Google

70. Van Vyve T, Chanez P, Bernard A. Protein content in BAL fluid of patients with asthma and control subjects. J Allergy Clin Immunol, 1995; 95:60-68. Cerca con Google

71. Lensmar C, Nord M, Gudmundsson GH, Roquet A, Andersson O, Jornvall H, Eklund A, Grunewald J, Agerberth B. Decresed pulmonary levels of the anti-inflammatory Clara cell 16 kda protein after induction of airway inflammation in asthmatics. CMLS, Cell Mol Life Sci, 2000; 57:976-981. Cerca con Google

72. Gioldassi XM, Papidimitriou H, Mikraki V, Karamanos NK. Clara cell secretory protein: determination of serum levels by an enzyme immunoassay and its importance as an indicator of bronchial asthma in children. Journal of Pharmaceutical and Biomedical Analysis, 2004; 34:823-826. Cerca con Google

73. Martin AC, Lang IA, Khoo SK, Zhang G, Rueter K, Teoh L, Taheri S, Hayden CM, Geelhoed GC, Goldblatt J, Le Souef PN. Acute asthma in children: relationships among CD14 and CC16 genotypes, plasma levels and severity. Am J Respir Crit Care Med, 2006;173: 617-622. Cerca con Google

74. Blomberg A, Mudway I, Svensson M, Hagenbjork-gustafsson A, Thomasson L, Helleday R, Dumont X, Forsberg B, Nordberg G, Bernard A. Clara cell protein as a biomarker for ozone-induced lung injury in Humans. Eur Respir J, 2003; 22:883-888. Cerca con Google

75. Arsalane K, Broeckaert F, Knoops B, Wiedig M, Tobeau G, Bernard A. Clara cell specific protein (CC16) expression after acute lung inflammation induced by intratracheal lipopolysaccharide administration. Am J Respir Crit Care Med, 2000; 161: 1624-1630. Cerca con Google

Download statistics

Solo per lo Staff dell Archivio: Modifica questo record